Pulmatrix Inc.
Pulmatrix is a biopharmaceutical company dedicated to developing and commercializing innovative inhaled therapies for serious pulmonary diseases. Using their proprietary iSPERSE™ technology, they create small, dense, and dispersible particles for highly efficient drug delivery into the lungs. Their mission is to improve patient care by expanding horizons for respiratory and non-respiratory therapies, with a focus on conditions like migraine, ABPA, and AECOPD. They collaborate with strategic partners like Cipla and are advancing a pipeline of inhaled medicines, including PUR3100 for migraine, PUR1900 for ABPA, and PUR1800 for AECOPD.
Industries
Nr. of Employees
small (1-50)
Pulmatrix Inc.
431 Glebe Point Road, Glebe, Sydney, NSW 2037, Australia
Patents
Respirably dry powder comprising calcium lactate, sodium chloride and leucine
US-8758824-B2
View Details
Respirably dry powder comprising calcium lactate, sodium chloride and leucine
US-8758824-B2
View DetailsProducts
PUR3100
An inhaled dry powder formulation of dihydroergotamine (DHE) engineered for oral inhalation to treat acute migraine; under clinical development with early-phase safety, tolerability and pharmacokinetic evaluation.
PUR1900
An inhaled dry powder formulation of itraconazole engineered to increase pulmonary exposure and reduce systemic plasma exposure for the treatment of allergic bronchopulmonary aspergillosis (ABPA); currently in clinical studies.
PUR1800
A narrow-spectrum kinase inhibitor (targets p38 MAPK, Src and Syk kinases) formulated as an inhaled dry powder for treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); in clinical development.
PUR3100
An inhaled dry powder formulation of dihydroergotamine (DHE) engineered for oral inhalation to treat acute migraine; under clinical development with early-phase safety, tolerability and pharmacokinetic evaluation.
PUR1900
An inhaled dry powder formulation of itraconazole engineered to increase pulmonary exposure and reduce systemic plasma exposure for the treatment of allergic bronchopulmonary aspergillosis (ABPA); currently in clinical studies.
PUR1800
A narrow-spectrum kinase inhibitor (targets p38 MAPK, Src and Syk kinases) formulated as an inhaled dry powder for treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); in clinical development.
Services
Performance and robustness testing for aerosol-generating products and associated packaging, including delivered dose uniformity, aerodynamic size distribution, cascade impactor/NGI/MSLI studies and particle size statistics.
End-to-end formulation support for inhalation products including API/excipient customization, DPI formulation optimization, nebulizer and nasal formulations, lab-scale pMDI filling, and device parameter guidance.
Custom method development and validation for analytical assays and aerosol testing, with full analytical services including HPLC and HPLC-MS.
Preclinical toxicity, transport and pharmacology studies using respiratory-specific cell types and bespoke deposition/transport models to assess epithelial response, inflammation and pharmacokinetics.
Consulting on device parameters, testing protocols, formulation stability, packaging robustness, filling line troubleshooting, biosimilars/generics issues, and patent litigation support.
Performance and robustness testing for aerosol-generating products and associated packaging, including delivered dose uniformity, aerodynamic size distribution, cascade impactor/NGI/MSLI studies and particle size statistics.
End-to-end formulation support for inhalation products including API/excipient customization, DPI formulation optimization, nebulizer and nasal formulations, lab-scale pMDI filling, and device parameter guidance.
Custom method development and validation for analytical assays and aerosol testing, with full analytical services including HPLC and HPLC-MS.
Preclinical toxicity, transport and pharmacology studies using respiratory-specific cell types and bespoke deposition/transport models to assess epithelial response, inflammation and pharmacokinetics.
Consulting on device parameters, testing protocols, formulation stability, packaging robustness, filling line troubleshooting, biosimilars/generics issues, and patent litigation support.
Expertise Areas
- Inhalation formulation development
- Particle engineering for dry powder delivery
- Aerosol characterization and inhaler performance testing
- Preclinical respiratory toxicology and cell-based assays
Key Technologies
- Dry powder particle engineering
- Spray drying
- Milling and particle size reduction
- Laser diffraction aerosol measurement
News & Updates
Clinical trials for PUR1900 in ABPA and other conditions
Ongoing clinical trials to evaluate safety, tolerability, and efficacy of PUR1900 for ABPA and related diseases.
Pipeline development of inhaled therapies for migraine and respiratory diseases
Advancement of PUR3100 for migraine and other pipeline products utilizing iSPERSE™ technology.
Pulmatrix's iSPERSE™ technology creates small, dense, and dispersible particles
Innovative particle engineering technology enabling highly efficient drug delivery to the lungs.
Pulmatrix collaborates with Cipla on PUR1900 anti-fungal program
Partnership validates development plan and potential of iSPERSE™ for respiratory therapies.
Development of PUR3100 for migraine
Progressing through clinical trials with the goal of providing fast, effective, and long-lasting relief for migraine sufferers.
Development of PUR1900 for ABPA
Inhaled antifungal formulation using iSPERSE™ technology, currently in clinical trials.
Clinical trials for PUR1900 in ABPA and other conditions
Ongoing clinical trials to evaluate safety, tolerability, and efficacy of PUR1900 for ABPA and related diseases.
Pipeline development of inhaled therapies for migraine and respiratory diseases
Advancement of PUR3100 for migraine and other pipeline products utilizing iSPERSE™ technology.
Pulmatrix's iSPERSE™ technology creates small, dense, and dispersible particles
Innovative particle engineering technology enabling highly efficient drug delivery to the lungs.
Pulmatrix collaborates with Cipla on PUR1900 anti-fungal program
Partnership validates development plan and potential of iSPERSE™ for respiratory therapies.
Development of PUR3100 for migraine
Progressing through clinical trials with the goal of providing fast, effective, and long-lasting relief for migraine sufferers.
Development of PUR1900 for ABPA
Inhaled antifungal formulation using iSPERSE™ technology, currently in clinical trials.